Cargando…
Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice
Multiple variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have spread around the world, but the neutralizing effects of antibodies induced by the existing vaccines have declined, which highlights the importance of developing vaccines against mutant virus strains. In this stud...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705015/ https://www.ncbi.nlm.nih.gov/pubmed/34960131 http://dx.doi.org/10.3390/vaccines9121383 |
_version_ | 1784621843362086912 |
---|---|
author | Shi, Juan Jin, Xiaoxiao Ding, Yan Liu, Xiaotao Shen, Anran Wu, Yandan Peng, Min Shen, Chuanlai |
author_facet | Shi, Juan Jin, Xiaoxiao Ding, Yan Liu, Xiaotao Shen, Anran Wu, Yandan Peng, Min Shen, Chuanlai |
author_sort | Shi, Juan |
collection | PubMed |
description | Multiple variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have spread around the world, but the neutralizing effects of antibodies induced by the existing vaccines have declined, which highlights the importance of developing vaccines against mutant virus strains. In this study, nine receptor-binding domain (RBD) proteins of the SARS-CoV-2 variants (B.1.1.7, B.1.351 and P.1 lineages) were constructed and fused with the Fc fragment of human IgG (RBD-Fc). These RBD-Fc proteins contained single or multiple amino acid substitutions at prevalent mutation points of spike protein, which enabled them to bind strongly to the polyclonal antibodies specific for wild-type RBD and to the recombinant human ACE2 protein. In the BALB/c, mice were immunized with the wild-type RBD-Fc protein first and boosted twice with the indicated mutant RBD-Fc proteins later. All mutant RBD-Fc proteins elicited high-level IgG antibodies and cross-neutralizing antibodies. The RBD-Fc proteins with multiple substitutions tended to induce higher antibody titers and neutralizing-antibody titers than the single-mutant RBD-Fc proteins. Meanwhile, both wild-type RBD-Fc protein and mutant RBD-Fc proteins induced significantly decreased neutralization capacity to the pseudovirus of B.1.351 and P.1 lineages than to the wild-type one. These data will facilitate the design and development of RBD-based subunit vaccines against SARS-COV-2 and its variants. |
format | Online Article Text |
id | pubmed-8705015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87050152021-12-25 Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice Shi, Juan Jin, Xiaoxiao Ding, Yan Liu, Xiaotao Shen, Anran Wu, Yandan Peng, Min Shen, Chuanlai Vaccines (Basel) Article Multiple variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have spread around the world, but the neutralizing effects of antibodies induced by the existing vaccines have declined, which highlights the importance of developing vaccines against mutant virus strains. In this study, nine receptor-binding domain (RBD) proteins of the SARS-CoV-2 variants (B.1.1.7, B.1.351 and P.1 lineages) were constructed and fused with the Fc fragment of human IgG (RBD-Fc). These RBD-Fc proteins contained single or multiple amino acid substitutions at prevalent mutation points of spike protein, which enabled them to bind strongly to the polyclonal antibodies specific for wild-type RBD and to the recombinant human ACE2 protein. In the BALB/c, mice were immunized with the wild-type RBD-Fc protein first and boosted twice with the indicated mutant RBD-Fc proteins later. All mutant RBD-Fc proteins elicited high-level IgG antibodies and cross-neutralizing antibodies. The RBD-Fc proteins with multiple substitutions tended to induce higher antibody titers and neutralizing-antibody titers than the single-mutant RBD-Fc proteins. Meanwhile, both wild-type RBD-Fc protein and mutant RBD-Fc proteins induced significantly decreased neutralization capacity to the pseudovirus of B.1.351 and P.1 lineages than to the wild-type one. These data will facilitate the design and development of RBD-based subunit vaccines against SARS-COV-2 and its variants. MDPI 2021-11-24 /pmc/articles/PMC8705015/ /pubmed/34960131 http://dx.doi.org/10.3390/vaccines9121383 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shi, Juan Jin, Xiaoxiao Ding, Yan Liu, Xiaotao Shen, Anran Wu, Yandan Peng, Min Shen, Chuanlai Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice |
title | Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice |
title_full | Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice |
title_fullStr | Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice |
title_full_unstemmed | Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice |
title_short | Receptor-Binding Domain Proteins of SARS-CoV-2 Variants Elicited Robust Antibody Responses Cross-Reacting with Wild-Type and Mutant Viruses in Mice |
title_sort | receptor-binding domain proteins of sars-cov-2 variants elicited robust antibody responses cross-reacting with wild-type and mutant viruses in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705015/ https://www.ncbi.nlm.nih.gov/pubmed/34960131 http://dx.doi.org/10.3390/vaccines9121383 |
work_keys_str_mv | AT shijuan receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice AT jinxiaoxiao receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice AT dingyan receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice AT liuxiaotao receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice AT shenanran receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice AT wuyandan receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice AT pengmin receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice AT shenchuanlai receptorbindingdomainproteinsofsarscov2variantselicitedrobustantibodyresponsescrossreactingwithwildtypeandmutantvirusesinmice |